Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Double-Blind Efficacy and Safety of Ezetimibe (SCH 58235) 10 MG in Addition to Atorvastatin in Subjects With Coronary Heart Disease or Multiple Cardiovascular Risk Factors and With Primary Hypercholesterolemia Not Controlled by a Starting Dose (10 mg) of Atorvastatin

NCT03867318 is registered in ClinicalTrials.gov with Organon and Co as lead sponsor.

NCT NCT03867318
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03867318 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Double-Blind Efficacy and Safety of Ezetimibe (SCH 58235) 10 MG in Addition to Atorvastatin in Subjects With Coronary Heart Disease or Multiple Cardiovascular Risk Factors and With Primary Hypercholesterolemia Not Controlled by a Starting Dose (10 mg) of Atorvastatin
Lead sponsor
Organon and Co
Phase
Phase 3
Overall status
Completed
Start date
April 24, 2000
Completion date
November 16, 2001
Enrollment
621 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hypercholesterolemia